Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE)

Next Previous
Trial Profile

BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 15 Jun 2024 Results (n=10) reporting safety and efficacy data presented at the 25th Annual Congress of the European League Against Rheumatism
  • 12 Jun 2024 According to an iCell Gene Therapeutics Media Release, the company plans to file IND application for BCMA-CD19 cCAR T cells in US and China.
  • 12 Jun 2024 According to an iCell Gene Therapeutics Media Release, data from this trial will be presented a the European Alliance of Associations for Rheumatology (EULAR) 2024 Congress taking place from June 12-15 in Vienna, Austria.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top